Royalty Report: Medical, Device, Therapeutic – Collection: 3030

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Device
  • Therapeutic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3030

License Grant
Licensor, the son of  the original founder of Licensee, hereby assign and grant to Licensee for the TERM and subject to the provisions of this Agreement, with right to grant licenses to third parties consistent with the terms of this Agreement, all of the INVENTORS' right, title and interest worldwide in and to (a) the INVENTIONS, and (b) the SUBJECT PATENTS.
License Property
INVENTORS have invented and are the sole owners of an INVENTION relating to an apparatus and method for removing HIV and other viruses from the blood.

Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Most recently, we discovered our Hemopurifier® effectively captures tumor-secreted exosomes, known to kill off the immune cells of those afflicted with cancer.

An application for a provisional patent was filed by INVENTORS on August 31, 1998 with the United States Patent and Trademark Office under serial number 60/098,477 with respect to such INVENTION, and US utility application Serial No. 09/385166 and International Application No. PCT/US 99-19448 were filed by INVENTORS with respect to such INVENTION.

Field of Use
'FIELD OF USE' shall mean devices and methods for removing HIV and other viruses from the blood employing a filtration device having antibodies and/or DNA fragments immobilized on a material and retained by a membrane that allows serum containing virus to interact with the antibodies and/or DNA, including but not limited to such devices and methods as described in SUBJECT PATENTS.

IPSCIO Record ID: 1412

License Grant
INVENTOR, the son of LICENSEE's founder, hereby assign and grant to LICENSEE, for the TERM and subject to the provisions of this Agreement, with right to grant licenses to third parties consistent with the terms of this Agreement, all of the INVENTORS' right, title and interest worldwide in and to (a) the INVENTIONS, and (b) the SUBJECT PATENTS.
License Property
Licensor/Inventors have invented and are the sole owners of an Invention relating to an apparatus and method for removing HIV and other viruses from the blood using the Hemopurifier(TM).
Field of Use
The Licensee is advancing the Hemopurifier(TM) technology as a treatment to enhance and prolong current drug therapies by removing the viral strains that cause drug resistance. The Hemopurifier(TM) is also designed to prolong life for infected patients who have become drug resistant and have no other treatment options.

IPSCIO Record ID: 3309

License Grant
The Licensee has been exclusively assigned all rights and title to and interest in an invention and related worldwide patent rights for a method to treat cancer under an assignment Agreement with the London Licensor. The invention provides for the 'Depression of anticancer immunity through extracorporeal removal of microvesicular particles' (including exosomes) for which a patent was allowed by the U.S. Patent and Trademark Office (USPTO) in 2012 and patent applications have been filed abroad by us.  Under the License Agreement, the Licensor sold and assigned all of its rights, title and interest in the worldwide patents to us.
License Property
The IP relates to a method to treat cancer.
Field of Use
The Licensee creates medical devices to address unmet therapeutic needs in infectious disease, cancer and other life-threatening conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.